Dong Hongjuan, Wang Rui, Cheng Lu, Ma Shirong, Zhu Li, Zhao Jing, Gao Guangxun
Department of Hematology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.
Department of Pathology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China.
Front Oncol. 2025 Jul 9;15:1632039. doi: 10.3389/fonc.2025.1632039. eCollection 2025.
The current standard treatment for relapsed or refractory Hodgkin's lymphoma involves salvage chemotherapy followed by high-dose chemotherapy and sequential autologous stem cell transplantation. However, for patients who cannot tolerate intense chemotherapy or do not meet the conditions for autologous stem cell transplantation, there is a need to explore new treatment options. We report a case of an elderly patient with multiple relapses of classical Hodgkin's lymphoma who experienced repeated disease progression despite undergoing multiple lines of treatment including novel agents such as CD30 monoclonal antibody and PD-1 monoclonal antibody. The patient finally achieved sustained remission after receiving a combination therapy of lenalidomide and PD-1 monoclonal antibody. We hope to provide hematologists with a candidate treatment option for patients with relapsed or refractory Hodgkin's lymphoma through this case report.
复发或难治性霍奇金淋巴瘤的当前标准治疗包括挽救性化疗，随后进行大剂量化疗和序贯自体干细胞移植。然而，对于无法耐受强化化疗或不符合自体干细胞移植条件的患者，有必要探索新的治疗选择。我们报告了一例老年经典霍奇金淋巴瘤多次复发的患者，尽管接受了包括CD30单克隆抗体和PD-1单克隆抗体等新型药物在内的多线治疗，但疾病仍反复进展。该患者在接受来那度胺和PD-1单克隆抗体联合治疗后最终实现了持续缓解。我们希望通过本病例报告为血液科医生提供一种针对复发或难治性霍奇金淋巴瘤患者的候选治疗选择。
